Jameson, Gayle S <br/><br/>
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jan 2013 
 - 268-78 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-12-1201  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Heterocyclic Compounds, 4 or More Rings--administration & dosage<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Polyethylene Glycols--administration & dosage<br/>Topoisomerase I Inhibitors--administration & dosage<br/>Treatment Outcome